论文部分内容阅读
[目的]探讨冠脉病变程度Gensini评分与急性冠脉综合征(ACS)患者发生严重心血管不良事件(M ACE)之间的关系.[方法]记录78例ACS随访期间M ACE发生情况,按照是否发生M ACE分为M ACE组与无M ACE组,比较两组患者同型半胱氨酸(Hcy)、髓过氧化物酶(M PO)和Gensini评分的差异.[结果]M ACE组患者的Gensini评分为(65.77 ± 4.03)分,高于无M ACE组的(46.16 ± 5.02)分,且差异有显著性(P<0.01);两组患者的Hcy水平分别为(18.63 ± 4.37)μmol/L 和(15.21 ± 2.70)μmol/L;M PO 水平则分别为(4149.52 ± 955.41)pmol/L和(2302.74 ± 1107.83)pmol/L,两组比较差异有显著性(P <0.05).将影响ACS患者M ACE预后的各项因素以及Hcy、M PO和Gensini评分等变量进行多因素Logistic回归分析,结果表明Gensini评分可作为评估ACS患者1~6个月发生M ACE风险的独立预测因素.[结论]Gensini评分在预测M ACE发生风险方面存在着一定优势,准确率高,且Gensini评分与M ACE的发生风险呈正相关.“,”[Objective] To explore the relationship between Gensini score and major adverse cardiac events (MACE)in patients with coronary artery disease(ACS).[Methods]A total of 78 patients with coronary arter-y disease(ACS)from December 2015 to July 2016 were collected for the study.Based on the incidence of MACE during the follow-up period,patients were divided into the MACE group and No-MACE group.The differences of Homocysteine(Hcy),Myeloperoxidase(MPO)and Gensini scores between the two groups were recorded and analyzed.[Results]The MACE group had a Gensini score of(65.77 ± 4.03),which was higher than that of non-MACE group(46.16 ± 5.02);the difference was statistically significant(P <0.01).Levels of Hcy and MPO in the MACE group were(18.63 ± 4.37)μmol/L,(4149.52 ± 955.41)pmol/L,respectively, which were higher than those in No-MACE group(15.21 ± 2.70)μmol/L and(2302.74 ± 1107.83)pmol/L,re-spectively.The differences were statistically significant(P <0.05).Multivariate Logistic regression analysis was used to analyze the factors influencing the MACE prognosis of patients with ACS and the Hcy,MPO and Gensini scores during follow-up.The results showed that the Gensini score could be used as an independent predictor of MACE risk in ACS patients from 1 to 6 months of ACS.[Conclusion]The Gensini score has cer-tain advantage in predicting the risk of MACE with high accuracy.It has positive correlation between the oc-currence of MACE risk and Gensini score.